Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind trial of ustekinumab in moderately to severely active Crohn's disease
2008-000649-77Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ustekinumab in Crohn's disease (4 arms), sponsored by Janssen Biotech. Primary endpoint: Clinical response at Week 6. Started Sep 2008; status: completed.
02
Drugs
ustekinumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2008-000649-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000649-77.